Back
8-K ↗8-K ↗
RCKT
ROCKET PHARMACEUTICALS, INC.
Rocket Pharmaceuticals develops gene therapies using adeno-associated virus (AAV) and lentiviral vector technologies to treat rare genetic diseases, with a focus on blood disorders, metabolic conditions, and inherited cardiac diseases. The pipeline includes candidates in various development stages, from investigational programs through clinical trials, targeting conditions such as Fanconi Anemia, Leukocyte Adhesion Deficiency-I, Pyruvate Kinase Deficiency, and arrhythmogenic cardiomyopathy. Rocket operates across multiple regulatory jurisdictions including the FDA and European Medicines Agency as it advances its therapeutic candidates toward commercialization.
$3.48-54.39%1Y
RCKT · daily close · illustrative · 0 catalysts marked
Pipeline
UnknownIndication pending review
UnknownIndication pending review
UnknownIndication pending review
Catalyst Calendar
Past (3)
NOV 18
ReadoutRP-A501
“On November 18, 2024, the Company presented long-term safety and efficacy results from the Phase 1 RP-A501 study which showed that RP-A501 was generally well tolerated and all evaluable Danon disease patients demonstrated LAMP2 protein expression at 12 months (sustained up to 60 months) and reduction of left ventricular (LV) mass index by ≥10% at 12 months (sustained up to 54 months) after treatment.”
MAR 28
PDUFAKRESLADI (marnetegragene autotemcel; marne-cel)
“The PDUFA date set by the FDA is March 28, 2026.”